BTIG Research Upgrades Endologix To Buy, Shares Gain

Analysts at BTIG Research upgraded Endologix ELGX from Neutral to Buy. The target price for Endologix is set to $17. Endologix shares have dropped 17.30% over the past 52 weeks, while the S&P 500 index has surged 20.02% in the same period. Endologix's shares surged 2.93% to $13.68 in pre-market trading.